Clinical Trials Search Tool
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults.
Disease/Condition: SARS-COV-2
Location: Gresham
Ages: 6M – 5 years of age
Enrollment Opens: 04-25-2022
Enrollment Closes: TBD
Description:
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY,
TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3
PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY,
AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE
CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN
AND YOUNG ADULTS
Study ID: C4591007
To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at http://www.cyn3rgy.com
Posted by: Cyn3rgy Research | http://www.cyn3rgy.com